Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Eisai Establishes AiM Institute to Discover Human Biology Driven Precision Medicines

Eisai Inc.
Posted on: 15 Sep 16

PR Newswire

ANDOVER, Mass., Sept. 15, 2016

ANDOVER, Mass., Sept. 15, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the greater Boston biopharma hub. With 90 integrated scientists at a state-of-the-art research facility in Andover, Massachusetts, the Institute is focused on executing novel therapeutic targets validated by human genetics and related data to discover and develop precision medicines for some of the hardest-to-treat medical conditions including dementia, cancer and auto-immune diseases.

Eisai established the AiM institute as part of its new 10-year EWAY Strategic Plan, which was announced at the Global Information Meeting in March 2016. The institute is part of the Company's end-to-end business model that efficiently integrates discovery, clinical and commercial functions. The AiM Institute brings together scientists, technologies and expertise across quantitative, biological, chemistry and translational sciences to target three key therapeutic areas: Immuno-dementia, immuno-oncology and auto-immune indications.

  • In immuno-dementia, AiM is studying the subset of dementia patients with immune-driven pathology, targeting immune dysfunction and enhancing internal neuroimmune mechanisms identified by human genetics to develop novel targeted treatments for Alzheimer's disease and dementia;
  • In immununo-oncology, as the tumor microenvironment has emerged as a viable target to prevent and treat cancer tumor growth, AiM is utilizing its expertise in immune cell biology, genomics and small molecules to discover novel precision immunotherapies targeting myeloid lineage cells. One such therapy, E7046, is a first-in-class orally active EP4 receptor antagonist currently under clinical development; and
  • AiM is also building on Eisai's strengths in targeting toll-like receptors and prostaglandins with small molecules to prosecute genetically validated therapeutic targets for auto-immune indications, including for systemic lupus erythematosus (SLE).

While the opportunity provided by human genetics to disrupt the drug discovery process is well established, realizing this potential has been hampered by conventional biopharma models structured with several siloed research groups "supporting" one another. By contrast, the AiM Institute is premised upon innovation without borders, and the ownership of a focused portfolio by a dedicated and multi-disciplinary group of scientists with a single mission: realizing a new paradigm in human biology driven drug discovery.

"The AiM Institute combines the focus, agility and innovative culture of a 90-person biotech-like organization with Eisai's operational expertise and experience in bringing new medicines to patients," said Nadeem Sarwar, president of the Eisai AiM Institute

To achieve its mission, AiM has established and will continue to seek collaborations and strategic alliances with a broad spectrum of external scientific partners who complement its internal scientific expertise. Current AiM collaborations are focused on human genetics, functional genomics, assay development, structural biology, computational chemistry, library synthesis, compound screening, and translational biomarkers. In addition, AiM scientists are proactively involved in several "pre-competitive" research consortia, and are actively encouraged to contribute data to collaborations as well as publish research findings. To enable such collaboration, AiM has initiated a variety of flexible, innovative collaborative agreements concentrated on accelerating drug discovery.

To develop and accelerate its focused discovery portfolio, AiM is integrating multidisciplinary scientists within a single and dedicated research facility. The close scientific integration of AiM scientists enables the initiation of translational and biomarker-related research from project inception, providing a more seamless transition from preclinical discovery to clinical development.

The AiM Institute is organized around five scientific engines:

  • The Human Biology & Data Sciences Engine focuses on accessing, analyzing, integrating, interpreting and applying human biology data from several sources for the discovery and validation of novel therapeutic targets and biomarkers;
  • The Integrated Biology Engine validates therapeutic concepts by evaluating genetic variants in human cell systems and in vivo disease models to understand how genetic variation changes the function of targets to cause disease. This engine's end goal is to generate an extensive preclinical package for an investigational new drug (IND) application filing, including preclinical proof-of-concept and translational biomarkers for dose-setting and patient selection;
  • The Target Modulation Engine serves as the interface between chemistry and biology, connecting novel therapeutic targets with bioactive compounds. This engine focuses on accelerating drug discovery for human biology validated targets by developing hypotheses for target modulation mechanisms; experiment-supported structural biology; creation of target specific assays; selection of flexible, strategic screening approaches; and providing unique compound collections;
  • The Integrated Chemistry Engine utilizes combined expertise in medicinal, synthetic, screening, structural, translational, and platform chemistry to create innovative solutions for human biology validated targets. Building upon Eisai's success in structurally complex fully synthetic small molecule drugs, this engine will explore previously inaccessible areas of complex molecular spaces to address novel and previously undruggable targets; and
  • The Imaging Center of Excellence provides imaging expertise and in vivo applications to provide decision-making experimental data, strategies and solutions for global discovery and translational research. This engine applies MRI, CT, SPECT, and PET scanning, as well as radiochemistry solutions for neuroscience, oncology, immunology and drug safety.

To learn more about AiM, its research and team of scientists, please visit its website

Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at and follow us on Twitter and LinkedIn.

Eisai Co. Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care(hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit


Media Inquiries

Investor Inquiries

Patricia Councill

Ivor Macleod

Eisai Inc.

Eisai Inc.




Logo -

To view the original version on PR Newswire, visit:

SOURCE Eisai Inc.

PR Newswire

Last updated on: 15/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.